Abstract
The skeleton is the most frequent site of metastatic disease in breast cancer. A subset of patients develop bone-dominant disease without metastases to other organs. An attractive strategy is to utilize bone-targeted radiotherapy. This study was designed to determine the safety and preliminary efficacy of 166Ho-DOTMP, which localizes to bone, providing radiation to adjacent marrow and malignant cells. The limiting toxicity is myelosuppression, which can be overcome by autologous stem cell transplantation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
